Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis

Valeria B. Fernández Vallone, Erica L. Hofer, Hosoon Choi, Raúl H. Bordenave, Emilio Batagelj, Leonardo Feldman, Vincent La Russa, Daniela Caramutti, Federico Dimase, Vivian Labovsky, Leandro M. Martínez, Norma A. Chasseing

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Tumour cells can find in bone marrow (BM) a niche rich in growth factors and cytokines that promote their self-renewal, proliferation and survival. In turn, tumour cells affect the homeostasis of the BM and bone, as well as the balance among haematopoiesis, osteogenesis, osteoclastogenesis and bone-resorption. As a result, growth and survival factors normally sequestered in the bone matrix are released, favouring tumour development. Mesenchymal stem cells (MSCs) from BM can become tumour-associated fibroblasts, have immunosuppressive function, and facilitate metastasis by epithelial-to- mesenchymal transition. Moreover, MSCs generate osteoblasts and osteocytes and regulate osteoclastogenesis. Therefore, MSCs can play an important pro-tumorigenic role in the formation of a microenvironment that promotes BM and bone metastasis. In this study we showed that BM MSCs from untreated advanced breast and lung cancer patients, without bone metastasis, had low osteogenic and adipogenic differentiation capacity compared to that of healthy volunteers. In contrast, chondrogenic differentiation was increased. Moreover, MSCs from patients had lower expression of CD146. Finally, our data showed higher levels of Dkk-1 in peripheral blood plasma from patients compared with healthy volunteers. Because no patient had any bone disorder by the time of the study we propose that the primary tumour altered the plasticity of MSCs. As over 70 % of advanced breast cancer patients and 30-40 % of lung cancer patients will develop osteolytic bone metastasis for which there is no total cure, our findings could possibly be used as predictive tools indicating the first signs of future bone disease. In addition, as the MSCs present in the BM of these patients may not be able to regenerate bone after the tumour cells invasion into BM/bone, it is possible that they promote the cycle between tumour cell growth and bone destruction.

Original languageEnglish
Pages (from-to)317-332
Number of pages16
JournalClinical and Experimental Metastasis
Volume30
Issue number3
DOIs
StatePublished - Mar 1 2013

Fingerprint

Mesenchymal Stromal Cells
Lung Neoplasms
Bone Marrow
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Osteogenesis
Neoplasms
Intercellular Signaling Peptides and Proteins
Healthy Volunteers
Osteocytes
Bone Matrix
Epithelial-Mesenchymal Transition
Time and Motion Studies
Survival
Bone Diseases
Bone Development
Hematopoiesis
Immunosuppressive Agents
Bone Resorption

Keywords

  • Bone marrow
  • Cancer
  • Mesenchymal stem cell
  • Plasticity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis. / Fernández Vallone, Valeria B.; Hofer, Erica L.; Choi, Hosoon; Bordenave, Raúl H.; Batagelj, Emilio; Feldman, Leonardo; La Russa, Vincent; Caramutti, Daniela; Dimase, Federico; Labovsky, Vivian; Martínez, Leandro M.; Chasseing, Norma A.

In: Clinical and Experimental Metastasis, Vol. 30, No. 3, 01.03.2013, p. 317-332.

Research output: Contribution to journalArticle

Fernández Vallone, VB, Hofer, EL, Choi, H, Bordenave, RH, Batagelj, E, Feldman, L, La Russa, V, Caramutti, D, Dimase, F, Labovsky, V, Martínez, LM & Chasseing, NA 2013, 'Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis', Clinical and Experimental Metastasis, vol. 30, no. 3, pp. 317-332. https://doi.org/10.1007/s10585-012-9539-4
Fernández Vallone, Valeria B. ; Hofer, Erica L. ; Choi, Hosoon ; Bordenave, Raúl H. ; Batagelj, Emilio ; Feldman, Leonardo ; La Russa, Vincent ; Caramutti, Daniela ; Dimase, Federico ; Labovsky, Vivian ; Martínez, Leandro M. ; Chasseing, Norma A. / Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis. In: Clinical and Experimental Metastasis. 2013 ; Vol. 30, No. 3. pp. 317-332.
@article{d53ba840a102410a9bd8652e784fc61e,
title = "Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis",
abstract = "Tumour cells can find in bone marrow (BM) a niche rich in growth factors and cytokines that promote their self-renewal, proliferation and survival. In turn, tumour cells affect the homeostasis of the BM and bone, as well as the balance among haematopoiesis, osteogenesis, osteoclastogenesis and bone-resorption. As a result, growth and survival factors normally sequestered in the bone matrix are released, favouring tumour development. Mesenchymal stem cells (MSCs) from BM can become tumour-associated fibroblasts, have immunosuppressive function, and facilitate metastasis by epithelial-to- mesenchymal transition. Moreover, MSCs generate osteoblasts and osteocytes and regulate osteoclastogenesis. Therefore, MSCs can play an important pro-tumorigenic role in the formation of a microenvironment that promotes BM and bone metastasis. In this study we showed that BM MSCs from untreated advanced breast and lung cancer patients, without bone metastasis, had low osteogenic and adipogenic differentiation capacity compared to that of healthy volunteers. In contrast, chondrogenic differentiation was increased. Moreover, MSCs from patients had lower expression of CD146. Finally, our data showed higher levels of Dkk-1 in peripheral blood plasma from patients compared with healthy volunteers. Because no patient had any bone disorder by the time of the study we propose that the primary tumour altered the plasticity of MSCs. As over 70 {\%} of advanced breast cancer patients and 30-40 {\%} of lung cancer patients will develop osteolytic bone metastasis for which there is no total cure, our findings could possibly be used as predictive tools indicating the first signs of future bone disease. In addition, as the MSCs present in the BM of these patients may not be able to regenerate bone after the tumour cells invasion into BM/bone, it is possible that they promote the cycle between tumour cell growth and bone destruction.",
keywords = "Bone marrow, Cancer, Mesenchymal stem cell, Plasticity",
author = "{Fern{\'a}ndez Vallone}, {Valeria B.} and Hofer, {Erica L.} and Hosoon Choi and Bordenave, {Ra{\'u}l H.} and Emilio Batagelj and Leonardo Feldman and {La Russa}, Vincent and Daniela Caramutti and Federico Dimase and Vivian Labovsky and Mart{\'i}nez, {Leandro M.} and Chasseing, {Norma A.}",
year = "2013",
month = "3",
day = "1",
doi = "10.1007/s10585-012-9539-4",
language = "English",
volume = "30",
pages = "317--332",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis

AU - Fernández Vallone, Valeria B.

AU - Hofer, Erica L.

AU - Choi, Hosoon

AU - Bordenave, Raúl H.

AU - Batagelj, Emilio

AU - Feldman, Leonardo

AU - La Russa, Vincent

AU - Caramutti, Daniela

AU - Dimase, Federico

AU - Labovsky, Vivian

AU - Martínez, Leandro M.

AU - Chasseing, Norma A.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Tumour cells can find in bone marrow (BM) a niche rich in growth factors and cytokines that promote their self-renewal, proliferation and survival. In turn, tumour cells affect the homeostasis of the BM and bone, as well as the balance among haematopoiesis, osteogenesis, osteoclastogenesis and bone-resorption. As a result, growth and survival factors normally sequestered in the bone matrix are released, favouring tumour development. Mesenchymal stem cells (MSCs) from BM can become tumour-associated fibroblasts, have immunosuppressive function, and facilitate metastasis by epithelial-to- mesenchymal transition. Moreover, MSCs generate osteoblasts and osteocytes and regulate osteoclastogenesis. Therefore, MSCs can play an important pro-tumorigenic role in the formation of a microenvironment that promotes BM and bone metastasis. In this study we showed that BM MSCs from untreated advanced breast and lung cancer patients, without bone metastasis, had low osteogenic and adipogenic differentiation capacity compared to that of healthy volunteers. In contrast, chondrogenic differentiation was increased. Moreover, MSCs from patients had lower expression of CD146. Finally, our data showed higher levels of Dkk-1 in peripheral blood plasma from patients compared with healthy volunteers. Because no patient had any bone disorder by the time of the study we propose that the primary tumour altered the plasticity of MSCs. As over 70 % of advanced breast cancer patients and 30-40 % of lung cancer patients will develop osteolytic bone metastasis for which there is no total cure, our findings could possibly be used as predictive tools indicating the first signs of future bone disease. In addition, as the MSCs present in the BM of these patients may not be able to regenerate bone after the tumour cells invasion into BM/bone, it is possible that they promote the cycle between tumour cell growth and bone destruction.

AB - Tumour cells can find in bone marrow (BM) a niche rich in growth factors and cytokines that promote their self-renewal, proliferation and survival. In turn, tumour cells affect the homeostasis of the BM and bone, as well as the balance among haematopoiesis, osteogenesis, osteoclastogenesis and bone-resorption. As a result, growth and survival factors normally sequestered in the bone matrix are released, favouring tumour development. Mesenchymal stem cells (MSCs) from BM can become tumour-associated fibroblasts, have immunosuppressive function, and facilitate metastasis by epithelial-to- mesenchymal transition. Moreover, MSCs generate osteoblasts and osteocytes and regulate osteoclastogenesis. Therefore, MSCs can play an important pro-tumorigenic role in the formation of a microenvironment that promotes BM and bone metastasis. In this study we showed that BM MSCs from untreated advanced breast and lung cancer patients, without bone metastasis, had low osteogenic and adipogenic differentiation capacity compared to that of healthy volunteers. In contrast, chondrogenic differentiation was increased. Moreover, MSCs from patients had lower expression of CD146. Finally, our data showed higher levels of Dkk-1 in peripheral blood plasma from patients compared with healthy volunteers. Because no patient had any bone disorder by the time of the study we propose that the primary tumour altered the plasticity of MSCs. As over 70 % of advanced breast cancer patients and 30-40 % of lung cancer patients will develop osteolytic bone metastasis for which there is no total cure, our findings could possibly be used as predictive tools indicating the first signs of future bone disease. In addition, as the MSCs present in the BM of these patients may not be able to regenerate bone after the tumour cells invasion into BM/bone, it is possible that they promote the cycle between tumour cell growth and bone destruction.

KW - Bone marrow

KW - Cancer

KW - Mesenchymal stem cell

KW - Plasticity

UR - http://www.scopus.com/inward/record.url?scp=84875770209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875770209&partnerID=8YFLogxK

U2 - 10.1007/s10585-012-9539-4

DO - 10.1007/s10585-012-9539-4

M3 - Article

C2 - 23053744

AN - SCOPUS:84875770209

VL - 30

SP - 317

EP - 332

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 3

ER -